Business

Biotech, pharma, and money in science

Thermo Fisher Scientific

Biotech

Thermo Fisher gets into gene therapy with $1.7B deal for Brammer Bio

By Jonathan Saltzman — Boston Globe

STAT SPOTLIGHT

Biotech

Werewolf moves into a web of immunotherapy startups

By Kate Sheridan

advertisement

Distance treatment - mental health

Business

As patients tell apps they’re feeling suicidal, digital health startups scramble to respond

By Rebecca Robbins

advertisement

Tech and money bubble

Business

Digital health just had a record year. But is a day of reckoning ahead?

Alzheimers hands

Biotech

After the blowup of the biggest hope for Alzheimer’s, what’s next in the pipeline?

By STAT staff

Biotech

Alzheimer’s drug failure leaves Biogen in a precarious place

By Adam Feuerstein and Matthew Herper

Pharmalot

Pharmalittle: Biogen and Eisai halt Alzheimer’s drug trials; FDA allows sale of some blood pressure drugs in shortage

By Ed Silverman and Elizabeth Cooney

advertisement

Noubar Afeyan

Biotech

Flagship Pioneering raises $824 million in venture capital round, its most ever

By Jonathan Saltzman — Boston Globe

advertisement

Mother and child

Biotech

FDA approves first new drug developed for women with postpartum depression

By Adam Feuerstein

National Portrait Gallery - London

Business

Amid opioid allegations, plan for major Sackler family gift to London National Portrait Gallery is dropped

By Megan Thielking

Easier Heart Valves

Business

The astounding 19-year journey to a sea change for heart patients

By Matthew Herper

Dr. Steve Paul

Biotech

Biotech startup raises $68 million to further work on its treatment for schizophrenia

By Jonathan Saltzman — Boston Globe

Medical syringe

Biotech

A Regeneron drug dominates eczema treatment. With new data, a small biotech believes it can compete

By Adam Feuerstein

Haven

Business

What’s in a name? For the newly christened Haven, maybe another legal fight

By Casey Ross and Kate Sheridan

Overdrove the headlights

Biotech

‘We overdrove our headlights’: After his biotech startup fails, a CEO reflects on what went wrong

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

Harvard

In the Lab

Hedge fund investing $100 million in Harvard drug research

By Jonathan Saltzman — Boston Globe

Theranos

Business

Documentarian Alex Gibney has taken on Enron, Scientology — and now Theranos

By Rebecca Robbins

Hospital Cloud illo

Hospitals

As tech giants compete for contracts, hospitals shift their data to the cloud

DNA testing kit - 23andMe

Business

23andMe will tell you how your DNA affects your diabetes risk. Will it be useful?

By Rebecca Robbins

Fenway Park

Politics

How do you improve Medicare? Maybe you watch Major League Baseball

By Nicholas Florko

Elizabeth Holmes - PROMO for DOC

Business

Review: In ‘The Inventor,’ you can’t know Elizabeth Holmes’s secrets. And yet you can’t turn away

By Damian Garde

Vials

Pharmalot

What’s in a name? FDA changes course for biosimilar names and upsets generic makers

By Ed Silverman

Earth's City Lights at Night

The Pharmalot View

Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain

By Ed Silverman

Atul Gawande Innovation

Business

The Atul Gawande health care company finally has a name: Haven

Scott Robinson

Biotech

It costs $4,600 a month to rent a lab bench here. For startups, it’s the place to be

By Jonathan Saltzman — Boston Globe

Gottlieb vote

The Pharmalot View

Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator

By Ed Silverman

Purdue Pharma headquarters

Business

If Purdue Pharma declares bankruptcy, what would it mean for lawsuits against the opioid manufacturer?

By Andrew Joseph

Danielle D. Duplin

Business

Startups focused on aging have a home in new Kendall Square incubator

By Robert Weisman — Boston Globe

Blood samples stock

Biotech

Guardant’s blood test might replace biopsies for some lung cancer patients, study says

By Matthew Herper

« Previous Page